Safety assessment of inhaled xylitol in mice and healthy volunteers

Respiratory Research

Volumn 5, Issue , 2004, Pages

  Durairaj, Lakshmi ^a   Launspach, Janice ^a   Watt, Janet L ^a   Businga, Thomas R ^a   Kline, Joel N ^a,b   Thorne, Peter S ^b   Zabner, Joseph ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHACHOLINE; OVALBUMIN; SODIUM CHLORIDE; XYLITOL;

AEROSOL; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; NOSE CONGESTION; QUESTIONNAIRE; SENSITIZATION; SERUM OSMOLARITY; SPIROMETRY; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; ADULT; AIRWAY RESISTANCE; ANIMAL; C57BL MOUSE; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG; PHYSIOLOGY; REFERENCE VALUE;

ADMINISTRATION, INHALATION; ADULT; AIRWAY RESISTANCE; ANIMALS; COHORT STUDIES; FEMALE; HUMANS; LUNG; MALE; MICE; MICE, INBRED C57BL; REFERENCE VALUES; XYLITOL;

EID: 25444454817     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-5-13     Document Type: Article

References (52)

1. Travis SM, Singh PK, Welsh MJ: Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 2001, 13:89-95.
2. Lehrer RI, Ganz T: Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol 1999, 11:23-27.
3. Huttner KM, Bevins CL: Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res 1999, 45:785-794.
4. Bals R, Weiner DJ, Wilson JM: The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999, 103:303-307.
5. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic inlung that is inactivated in cystic fibrosis. Cell 1997, 88:553-560.
6. Bals R, Wang X, Wu Z, Freemann T, Bafna V, Zasloff M, Wilson JM: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998, 102:874-880.
7. Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, Greenberg EP, Welsh MJ: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999, 20:872-879.
8. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1999, 95:14961-14966.
9. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236.
10. Folkesson HG, Matthay MA, Frigeri A, Verkman AS: Transepithelial water permeability in microperfused distal airways. Evidence for channel-mediated water transport. J Clin Invest 1996, 97:664-671.
11. Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ: Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell 1998, 2:397-403.
12. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
13. Zabner J, Seiler M, Launspach J, Karp PH, Kearney WR, Look DC, Smith JJ, Welsh MJ: The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci U S A 2000, 97:11614-11619.
14. Makinen KK, Bennett CA, Hujoel PP, Isokangas PJ, Isotupa KP, Pape H. R. Jr., Makinen PL: Xylitol chewing gums and caries rates: a 40-month cohort study. J Dent Res 1995, 74:1904-1913.
15. Soderling E, Makinen KK, Chen CY, Pape H. R. Jr., Loesche W, Makinen PL: Effect of sorbitol, xylitol, and xylitol/sorbitol chewing gums on dental plaque. Caries Res 1989, 23:378-384.
16. Makinen KK: Long-term tolerance of healthy human subjects to high amounts of xylitol and fructose: general and biochemical findings. Int Z Vitam Ernahrungsforsch Beih 1976, 15:92-104.
17. Uhari M, Kontiokari T, Koskela M, Niemela M: Xylitol chewing gum in prevention of actue otitus media: double blind randomised trial. BMJ 1996, 313:1180-1184.
18. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G: Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997, 10:2449-2454.
19. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT: Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996, 153:1503-1509.
20. Pavia D, Thomson ML, Clarke SW: Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978, 117:199-203.
21. Shibuya Y, Wills PJ, Kitamura S: The effects of lactose on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Eur Respir J 1997, 10:321S.
22. Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP, Bautovich G: Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J 1996, 9:725-732.
23. Feng W, Nakamura S, Sudo E, Lee MM, Shao A, King M: Effects of dextran on tracheal mucociliary velocity in dogs in vivo. Pulm Pharmacol Ther 1999, 12:35-41.
24. O'Callaghan C, Milner AD, Webb MS, Swarbrick A: Nebulised water as a bronchoconstricting challenge in infancy. Arch Dis Child 1991, 66:948-951.
25. Barker R, Levison H: Effects of ultrasonically nebulized distilled water on airway dynamics in children with cystic fibrosis and asthma. J Pediatr 1972, 80:396-400.
26. Schoeffel RE, Anderson SD, Altounyan RE: Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed) 1981, 283:1285-1287.
27. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G: Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999, 159:1843-1848.
28. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, Bye PT: The effect of inhaled mannitol on bronchial mucusclearancein cystic fibrosis patients: a pilot study. Eur Respir J 1999, 14:678-685.
29. Kline JN, Waaldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998, 160:2555-2559.
30. Jain VV, Businga TR, Kitagaki K, George CL, O'Shaughnessy PT, Kline JN: Mucosal Immunotherapy with CpG Oligodeoxynucleotides Reverses a Murine Model of Chronic Asthma Induced by Repeated Antigen Exposure. Am J Physiol Lung Cell Mol Phsyiol 2003, 285:L1137-L1146.
31. Noseda A, Schmerber J, Prigogine T, Yernault JC: Perceived effect on shortness of breath of an acute inhalation of saline or terbutalline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992, 5:1043-1053.
32. Bijl-Hofland ID, Cloossterman SG, van Schayck CP, v d Elshout FJ, Akkermans RP, Folgering HT: Perception of respiratory sensation assessed by means of histamine challenge and threshold loading tests. Chest 2000, 117:954-959.
33. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized tobramycin study group. Chest 1997, 111:955-962.
34. Standardization of spirometry. American Thoracic Society 1994, 143:1215-1223.
35. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol 1991, 88:808-814.
36. Singh PK, Tack BF, McCray P. B. Jr., Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physlol 2000, 279:L799-L805.
37. White SH, Wimley WC, Selsted ME: Structure, function, and membrane integration of defensins. Curr Opin Struct Biol 1995, 5:521-527.
38. Lehrer RI, Ganz T: Defensins of vertebrate animals. Curr Opin Immunol 2002, 14:96-102.
39. Forster H, Boecker S, Walther A: Use of xylitol as sugar substitute in diabetic children. Fortschr Med 1977, 95:99-102.
40. Hauschildt S, Chalmers RA, Lawson AM, Schultis K, Watts RW: Metabolic investigations after xylitol infusion in human subjects. Am J Clin Nutr 1976, 29:258-273.
41. Huttunen JK: Serum lipids, uric acid and glucose during chronic consumption of fructose and xylitol in healthy human subjects. Int Z Vitam Ernahrungsforsch Beih 1976, 15:105-115.
42. Leutenegger AF, Goschke H, Stutz K, Mannhart H, Werdenberg J, Werdenberg D, Wolff G, Allgower M: Comparison between glurycose and a combination of glucose, fructose, and xylitol as carbohydrates for total parenteral nutrition of surgical intensive care patients. Am J Surg 1977, 133:199-205.
43. Conyers RA, Huber TW, Thomas DW, Rofe AM, Bais R, Edwards RG: A one-compartment model for calcium oxalate tissue deposition during xylitol infusions in humans. Int J Vitam Nutr Res Suppl 1985, 28:47-57.
44. Conyers RA, Rofe AM, Bais R, James HM, Edwards JB, Thomas DW, Edwards RG: The metabolic production of oxalate from xylitol. Int J Vitam Nutr Res Suppl 1985, 28:9-28.
45. Leidig P, Gerding W, Arns W, Ortmann M: Renal oxalosis with renal failure after infusion of xylitol. Dtsch Med Wochenschr 2001, 126: 1357-1360.
46. Mercer RR, Russell ML, Roggli VL, Crapo JD: Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol 1994, 10:613-624.
47. Wong BA, Tewksbury EW, Kelly JT, Asgharian B: Regional and lobar deposition of fine and coarse particles in the lungs of rats and mice. Toxicol Sci 2003, 72:39.
48. Hantos Z, Brusasco V: Assessment of respiratory mechanics in small animals: the simpler the better? J Appl Physiol 2002, 93:1196-1197.
49. Mitzner W, Tankersley C: Interpreting Penh in mice.J Appl Physiol 2003, 94:828-831.
50. Kline JN: Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol 2000, 247:211-225.
51. Kline JN, Kitagaki K, Businga TR, Jain VV: Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physlol 2002, 283:L170-L179.
52. McGowan SE, Smith J, Holmes AJ, Smith LA, Businga TR, Madsen MT, Kopp UC, Kline JN: Vitamin A deficiency promotes bronchial hyperreactivity in rats by altering muscarinic M(2) receptor function. Am J Physiol Lung Cell Mol Phsyiol 2002, 282:L1031-1039.